S

Sarepta Therapeutics Inc (SRPT)

Healthcare Biotechnology

14.90 $

Closing price · As of: 31. Jul 2026

🔔 Watch stock

Website

Email address First name (optional, for the greeting) New deep dive Scanner moves (enters / drops out) Notify me

Stock Watch

Stock Watch will tell you what changes at Sarepta Therapeutics Inc.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Website

Email address First name (optional, for the greeting) Sign up for free

Appears in These Scanners

This stock currently matches 1 of our scanner strategies — each hit links to the scanner.

Quality & Balance Sheet

Pros 80%

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Basics

Market Cap The value of the entire company on the market: share price times total shares outstanding.

1.6$B

Shares Outstanding Total number of shares issued. Price times share count gives market cap.

106Mio.

Float Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.

89.6%

Beta Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market.

0.2

Performance

Perf. 1M Price performance over the last month.

-1.60%

Perf. 3M Price performance over the last 3 months.

-14.80%

Perf. 6M Price performance over the last 6 months.

-23.70%

YTD Performance (%) Price performance since the start of the year (Year to Date).

-19.80%

52-Week-High Distance How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high.

-36.7%

Valuation

P/E Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E.

43.2

Forward P/E P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future.

5.6

PEG P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey.

159.3

P/B Price-to-book ratio: market value relative to book equity.

1.0

P/S Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable.

0.7

EV/EBITDA Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero.

19.4

Price/FCF Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up.

14.9

Profitability

Gross Margin Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power.

21.6%

EBIT Margin EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes.

49.1%

Net Margin Net margin: what's left of sales as profit after ALL costs, interest, and taxes.

3.0%

Return on Equity Return on equity: how much profit does the company generate per year on shareholders' equity?

4.9%

Return on Assets Return on assets: how much profit the company generates from its total assets (equity and debt combined).

0.02%

Balance Sheet & Safety

Equity Ratio Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet.

47.3%

Debt/Equity Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity.

0.7

Altman Z″ Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.

3.44

Piotroski Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.

6 out of 9

Growth

Sales Growth Last Quarter Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY).

-1.90%

EPS Growth Last Quarter Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY).

–

Sales Growth (Year) Sales growth in the last fiscal year versus the year before.

15.58%

Forward Sales Growth Sales growth analysts expect over the next 12 months — an estimate, not a guarantee.

-22.53%

Forward EPS Growth Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee.

-43.60%

Quality & Screener

Stage Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line.

4

RS Rating Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks.

26

Top 10%

EPS Rating Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth.

98

Piotroski Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.

6 out of 9

Fundamental Rating Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below.

C (51 out of 100)

Altman Z″ Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.

3.44

AI Rating

–

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Quarterly Figures

About the Company

Sarepta Therapeutics, Inc., ein biopharmazeutisches Unternehmen in der kommerziellen Phase, konzentriert sich auf Entdeckung und Entwicklung von RNA-gerichteten Therapeutika, einer siRNA-Plattform, Gentherapie und anderen genetischen Therapiemodalitäten zur Behandlung seltener Erkrankungen.

Employees	835
Headquarters	Cambridge, MA
Website	sarepta.com
IPO Date	3. Jun 1997
Next Earnings	5. Aug 2026

Management

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Insider Transactions

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.